Navigation Links
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Date:12/14/2007


Worldwide Rights for All Potential Uses, Excluding U.S. and Japan

No Other Existing Therapeutic Treatment for Celiac Disease

BASINGSTOKE, England and PHILADELPHIA, December 14 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announces that it has acquired the worldwide rights, excluding the U.S. and Japan, to AT-1001 from Alba Therapeutics Corporation (Alba). AT-1001 is Alba's lead inhibitor of barrier dysfunction in various gastrointestinal disorders that is currently in Phase 2 development for the treatment of Celiac disease. Shire has acquired rights to all uses for AT-1001, which may also be studied for the treatment of Crohn's disease and other indications.

Matthew Emmens, Chief Executive Officer, commented: "The licensing of AT-1001 from Alba is a natural fit to our growing portfolio of gastrointestinal products. This product will be marketed to specialist physicians and we would expect to use our existing European sales force that is currently establishing relationships and expertise in the GI area through the marketing of MEZAVANT XL."

Financial terms of the license are geared to the successful development and commercialization of the product. Shire will pay Alba an upfront license fee of $25 million and further development and sales-based milestones totalling to a maximum of $300.5M should the product reach blockbuster status. Shire will also pay royalties on net sales of the product, with tiered, single or double digit royalty rates.

Alba and Shire will form a joint development committee to monitor R&D activities of AT-1001. Alba will fund all development until AT-1001 has completed Proof of Concept, which is expected to be in the first half of 2009, after which Shire and Alba will share equally development costs under a joint development plan.

About Celiac disease:

Celiac disease is a T-cell mediated auto-immune dis
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... PHILADELPHIA , Feb. 26, 2015  Spark Therapeutics (NASDAQ: ... its management team will participate in the Cowen and ... at 9:40 a.m., Eastern, at the Boston Marriott Copley ... a Spark Therapeutics presentation from the Cowen conference, please ... Events" section of the Spark Therapeutics website at ...
(Date:2/26/2015)... 26, 2015 On Wednesday, February 25, ... a nationwide Clostridium difficile (C. diff) awareness movement, lauded ... study by the Centers for Disease Control & Prevention ... half a million infections among Americans in a single ... , The study also estimates that 29,000 patients ...
(Date:2/26/2015)... 26, 2015 Phosphate Therapeutics, ... the first pivotal trial of PT20 in subjects ... disease (DD-CKD), has completed as the pre-specified number ... invented by leading UK-based scientists from the Medical ... is a novel phosphate binder that is based ...
(Date:2/25/2015)... 25, 2015 truBrain , creator ... in this week,s Power Pitch segment of CNBC,s  ... the company,s traction and growth strategy, as well ... funding site CircleUp. The segment highlights ... validated by neurotechnology, while also discussing its decision ...
Breaking Biology Technology:Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3CNBC's Power Lunch Features Neurotechnology Start-up truBrain 2
... researchers have found that the body,s innate ability to ... more effective and less costly artificial respirators. The new ... or paralysis currently necessary for some patients on mechanical ... adapt to recurring stimuli, is the focus of work ...
... Rice University chemists have discovered a way to load ... gold spheres. The result is a tiny ball, many times ... drug. , Paclitaxel, which is sold under the brand name ... works. , "Paclitaxel is one of the most effective anti-cancer ...
... new approach to discover life on Mars were successfully ... low-Earth orbit experiment to assess their survivability in the ... The new approach is based on technology similar to ... are embodied in the Life Marker Chip (LMC) experiment, ...
Cached Biology Technology:MIT: Leveraging learning for artificial respiration 2Taxol bristle ball: a wrench in the works for cancer 2Life on Mars 'pregnancy test' successfully launched 2
(Date:1/22/2015)... TORONTO , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the ... announced the launch of its new website design. ... in its infancy", says Peter O,Neill , founder and ... ever, the industry needs involvement from the key players on ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... has revealed that the extremely hot, dry and windy conditions ... ,horizontal convective rolls, -similar to streamers of wind flowing through ... study is the first of its kind to produce such ... provides insights for future fire management and warning systems. ...
... looking for information on the evolution and function ... Ravosa is your man. His integrative research ... the mammalian musculoskeletal system during development and across ... increasingly central role of the chewing complex in ...
... international research collaboration recently demonstrated progress in protecting cassava ... disease, in a confined field trial in Uganda using ... planted in November 2010 following approval by the National ... in November 2011 and results were published in the ...
Cached Biology News:Unusual weather events identified during the Black Saturday bushfires 2Notre Dame researcher is shedding light on how jaws evolve 2Researchers demonstrate control of devastating cassava virus in Africa 2
...
...
... Mouse polyclonal antibody raised against ... Immunogen: K6HF ... a.a) partial recombinant protein with ... Accession Number: NM_004693 ...
... role in the regulation of signaling pathways ... variants have been reported that affect both ... pathways. With Apoptosis and Cell Death ... profiling and at the same time detect ...
Biology Products: